The story · written by gpt-6,
Zimbabwe published regulations on 27 April 2018 allowing licensed cannabis production for medicinal and scientific purposes. Producers could obtain five-year licences under rules covering cultivation, processing, security and handling. The published application fee for a production licence was US$50,000.
Production gained a defined licensing route
Zimbabwe’s criminal code already distinguished lawful professional handling of drugs from offences involving possession, use, personal growing and dealing. The new regulations set out how an applicant could obtain permission to produce cannabis for medicine or research.
Production covered the crop and the work after harvest: drying, extraction, packaging, labelling, storage and processing. The regulations required applications to the Health Minister with site plans, security clearances and descriptions of the proposed activities.
Applicants also had to meet the rules on residence, company incorporation and personnel, subject to the available exemptions. A separate research application carried a US$5,000 fee in the original schedule.
A licence came with security and quality duties
A producer had to nominate people responsible for activities at the site. Licences identified authorised activities, locations and the period of permission.
The rules required restricted access, perimeter monitoring and intrusion detection. They also addressed growing conditions, water and soil quality, pesticide use, testing, packaging and record keeping. These obligations followed the cannabis through production and supply.
The original schedule listed further charges, including inspection and annual-return fees. A five-year licence therefore involved continuing duties as well as the initial application.
The first licences arrived the following year
The medicines regulator’s 2022 annual report says the first licence was issued in 2019. By its review, fifty-nine licences had been issued, with fifty-eight still active as licences.
The inspection picture showed different stages of development. Inspectors had witnessed cannabis cultivation at five sites, while eighteen visited sites had no development and eleven were under construction. Other sites were concentrating on hemp or had yet to be inspected.
The regulator described cannabis production at that time as being for export, with local use limited to research and development.
Hemp and CBD developed separate routes
Industrial-hemp authorisation in 2019 and detailed permits in 2020 added another agricultural route. The 2022 opening for CBD medicine applications brought a product-registration process for hemp-based complementary medicines.
Together, these developments shaped a licensed industry in Zimbabwe. The early inspection findings also showed how much work remained between receiving permission and operating a producing farm.[1][2][3]
Listed for context. No score change is recorded for Zimbabwe here.
References
- Zimbabwe Government Gazette — medicinal and scientific cannabis production regulations, SI 62 of 2018Gazette footer 27 April 2018; sections 3–8, 22–32, 53–64, 81–83 and First Schedulearchived
- Medicines Control Authority of Zimbabwe — 2022 Annual ReportPrinted pages 53–55 and 60: production licences, inspection findings and hemp-based CBD applicationsarchived
- Veritas — Criminal Law (Codification and Reform) Act, consolidated to September 2023Sections 155–161, printed pages 64–67; hemp text cross-checked against enacted Act 10 of 2023archived
Checked. The date and the event were compared with a source that was read.